GL1X · GenesisL1 explorer

MolNFT v1 · #118685 · protein

Structure of HLA-A2:01 with peptide Y9L

5F9J · HLA class I histocompatibility antigen, a-2 alpha chain: “Structure of HLA-A2:01 with peptide Y9L”. X-ray diffraction, 4 pockets (best druggability 0.68). MolNFT v1 #118685 on GenesisL1: 3D structure, binding sites and pockets in…

PDB
5F9J
Type
protein
Length
381 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
HLA class I histocompatibility antigen, a-2 alpha chain; Beta-2-microglobulin; Peptide Y9L
UniProt
P01892, P61769
Pockets
4 · best druggability 0.68

Structure

x-ray diffraction · 3 distinct chains · 19% helix, 42% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AHLA class I histocompatibility antigen, a-2 alpha chainprotein27427% helix, 40% strandP01892
BBeta-2-microglobulinprotein980% helix, 50% strandP61769
CPeptide Y9Lprotein90% helix, 0% strand—

Ligands and binding sites

  • GOL · Glycerol · additive · 3 copies · chains A, B, C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15850.680.7753GOL
21400.500.7923GOL
31050.410.7720empty
4650.310.7515empty

Interfaces

2 interfaces between chains.

  • A–B · 1248 Ų buried · 18 hydrogen bonds · protein-protein
  • A–C · 841 Ų buried · 11 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 3 disulfide (disulfide).

Compared structures

  • 5F9J · Structure of HLA-A2:01 with peptide Y9L · the same entry in another collection · chain A against A, TM-score 1.00
  • P61769 · AlphaFold monomer V2.0 prediction for beta-2-microglobulin (P61769) · a predicted model of the same protein · chain B against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.